Arix Bioscience

About

Portfolio · 3

Atox Bio

Immunomodulators for Treatment of Infectious and Inflammatory Diseases

Led ★ 1 round $30.0M committed Latest: 2017-12

Mitoconix Bio

Therapeutics for Neurodegenerative Diseases

1 round $20.0M committed Latest: 2017-06

LogicBio Therapeutics

Gene Therapy for Genetic and Infectious Diseases

1 round $45.0M committed Latest: 2017-06

Investment activity

1 portfolio exit on record.

Q&A

What is Arix Bioscience's primary investment focus?

Arix Bioscience primarily focuses on investments in the Health Tech & Life Sciences sector, with all three of its portfolio companies operating in this area.

Can you name some of Arix Bioscience's portfolio companies?

Arix Bioscience's portfolio includes Atox Bio, which develops immunomodulators.

What was a notable exit for Arix Bioscience?

Arix Bioscience had a notable exit in October 2018 when LogicBio Therapeutics went public on NASDAQ with a valuation of $219.4M, having raised $70M in capital.

What stages of funding does Arix Bioscience typically participate in?

Arix Bioscience has participated in various funding stages, including A Round, B Round, and F Round investments.

When was Arix Bioscience most active in making new portfolio investments?

Arix Bioscience was active in June 2017 and December 2017, making new portfolio investments during those periods.

What is the typical investment range for Arix Bioscience?

Arix Bioscience's investment range is typically between $20M and $45M.